Here are five recent news updates on gastroenterology and endoscopy companies.
Barclays analysts raised the price target of Boston Scientific shares from $19 to $20. Boston Scientific stock has an average rating of "buy."
Check-Cap announced the units sold in its initial public offering will separate on March 18. Each unit consists of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share.
Seven patients were infected with carbapenem-resistant Enterobacteriaceae after undergoing ERCP at UCLA Ronald Reagan Medical Center in Los Angeles. Olympus, the manufacturer of the scopes used in these cases, now faces lawsuits from five of these patients. Of the seven patients infected, two died.
PENTAX Medical named David Woods, previously the company's president of the Americas, its new chief marketing officer, effective April 1. Christopher Burton will succeed Mr. Woods as the company's president of the Americas.
Analysts at Jeffries Group downgraded Salix Pharmaceuticals' stock from a "buy" rating to a "hold" rating, according to a WKRB News & Analysis report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.